Literature DB >> 9554875

cycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system.

C Meier1, M Lorey, E De Clercq, J Balzarini.   

Abstract

The synthesis, hydrolysis, and antiviral evaluation of novel, lipophilic cycloSal-d4TMP derivatives 3a-h of the anti-HIV dideoxynucleoside 2',3'-dideoxy-2',3'-didehydrothymidine (d4T, 1) are reported. This pro-nucleotide concept has been designed to deliver d4TMP (2) by selective chemical hydrolysis. All compounds 3a-h were synthesized using phosphorus(III) chemistry in good yields and in somewhat lower yields using phosphorus(V) chemistry starting from substituted salicyl alcohols 6a-h. The phosphotriesters 3 were obtained without stereochemical preference with respect to the configuration at the phosphorus center as 1:1 diastereomeric mixtures. However, a few of the triesters 3 could be separated into the diastereomers by means of semipreparative HPLC. In a 1-octanol/phosphate buffer mixture, all compounds 3 exhibited 9-100-fold higher lipophilicity as judged from their Pa values as compared to d4T (1). Furthermore, in hydrolysis studies 3 decomposed under mild aqueous basic conditions releasing solely d4TMP (2) and the diols 6 following the designed tandem reaction sequence. A correlation of the electronic properties introduced by the substituents and the half-lives of triesters 3 was observed. Thus, by varying the substituent, the half-lives of 3 could be adjusted over a wide range of compounds still delivering d4TMP (2) selectively. Phosphotriesters 3 exhibited considerable activity against HIV-1 and HIV-2 in wild-type human T-lymphocyte (CEM/O) cells as well as mutant thymidine kinase-deficient (CEM/TK-) cells. Surprisingly, we observed a 3-80-fold difference in antiviral activity between the two diastereomers. Our data clearly prove that the cycloSal-d4TMPs deliver exclusively the nucleotide d4TMP not only under simulated hydrolysis conditions but also under cellular conditions and thus fulfill the thymidine kinase-bypass premise. Therefore, the cycloSal-nucleotide concept is the first reported pro-nucleotide system that delivers the dideoxynucleotide by a pH-driven, chemically activated, tandem reaction without the requirement of an enzymatic contribution.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9554875     DOI: 10.1021/jm970664s

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

Review 1.  Stavudine: an update of its use in the treatment of HIV infection.

Authors:  M Hurst; S Noble
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

Review 2.  Prodrugs of phosphonates and phosphates: crossing the membrane barrier.

Authors:  Andrew J Wiemer; David F Wiemer
Journal:  Top Curr Chem       Date:  2015

Review 3.  Phosphonate prodrugs: an overview and recent advances.

Authors:  Kenneth M Heidel; Cynthia S Dowd
Journal:  Future Med Chem       Date:  2019-07       Impact factor: 3.808

Review 4.  Synthesis of nucleoside phosphate and phosphonate prodrugs.

Authors:  Ugo Pradere; Ethel C Garnier-Amblard; Steven J Coats; Franck Amblard; Raymond F Schinazi
Journal:  Chem Rev       Date:  2014-08-21       Impact factor: 60.622

5.  Novel cyclic phosphate prodrug approach for cytochrome P450-activated drugs containing an alcohol functionality.

Authors:  Kristiina M Huttunen; Niina Mähönen; Jukka Leppänen; Jouko Vepsäläinen; Risto O Juvonen; Hannu Raunio; Hanna Kumpulainen; Tomi Järvinen; Jarkko Rautio
Journal:  Pharm Res       Date:  2007-02-15       Impact factor: 4.200

6.  Activities of masked 2',3'-dideoxynucleoside monophosphate derivatives against human immunodeficiency virus in resting macrophages.

Authors:  S Aquaro; O Wedgwood; C Yarnold; D Cahard; R Pathinara; C McGuigan; R Calio'; E de Clercq; J Balzarini; C F Perno
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

7.  Quinone-induced activation of Keap1/Nrf2 signaling by aspirin prodrugs masquerading as nitric oxide.

Authors:  Tareisha Dunlap; Sujeewa C Piyankarage; Gihani T Wijewickrama; Samer Abdul-Hay; Michael Vanni; Vladislav Litosh; Jia Luo; Gregory R J Thatcher
Journal:  Chem Res Toxicol       Date:  2012-10-18       Impact factor: 3.739

Review 8.  Prodrug approaches to improving the oral absorption of antiviral nucleotide analogues.

Authors:  Larryn W Peterson; Charles E McKenna
Journal:  Expert Opin Drug Deliv       Date:  2009-04       Impact factor: 6.648

9.  Restoration of the antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus by delivery of engineered thymidylate kinase to T cells.

Authors:  Arnon Lavie; Ying Su; Mahmood Ghassemi; Richard M Novak; Michael Caffrey; Nikolina Sekulic; Christian Monnerjahn; Manfred Konrad; James L Cook
Journal:  J Gen Virol       Date:  2008-07       Impact factor: 3.891

10.  Lipophilic prodrugs of nucleoside triphosphates as biochemical probes and potential antivirals.

Authors:  Tristan Gollnest; Thiago Dinis de Oliveira; Dominique Schols; Jan Balzarini; Chris Meier
Journal:  Nat Commun       Date:  2015-10-27       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.